Chemical Engineering @ChemengFiles.Com

The biomarkers are increasingly important in research of Alzheimer's disease as a method for risk assessment, primary screening, testing of new therapies and eventual primary intervention with better drugs when they develop. As part of its ongoing investigation and development of biomarkers for Alzheimer's and other diseases, BARC Central Laboratory is pleased to announce that it has joined the panel of inquiry into the Alzheimer's Association. As a sponsor, BARC will participate in the presentations of the panel and the subcommittee meetings related, focusing in particular on the evolution of biochemical biomarkers as indicators of prognosis and diagnosis.

It is believed that the high level changes cerebraldel Alzheimer's disease, including amyloid plaques and neurofibrillary tangles, begin many years before symptoms are evident or there is a death of brain cells. It is vital to identify those affected while still normal in terms of cognitive, so future therapies for modifying the disease can preserve normal functions. Testing and eventual use of these therapies require the identification of persons affected and "at risk" in order to bring them to clinical trials and direct and control therapies.

"Alzheimer's disease is undoubtedly a growing epidemic and a leading concern in public health. The Alzheimer's Association is the leading voluntary health organization in the U.S. research community is dedicated to eradicating Alzheimer enfermedaddel, BARC and aims to advance in the detection and primary tratamientodel Alzheimeren association with the Alzheimer's Association and other member of the panel of inquiry, "said Rudi Marien, CEO of BARC Group.

The panel of inquiry into the Alzheimer's Association is a consortium of scientists from the pharmaceutical, biotechnology, diagnostic, imaging and cognitive tests, in addition to the individuals and advisers of the Association. The aim of the roundtable is to facilitate research development and implementation of new treatments for Alzheimer enfermedaddel, speaking in a collective manner to overcome all obstacles in relation to research and development, clinical treatment and education of public health.